IMNM Key Statistics, Chart & Performance
The current stock price of IMNM is 19.76 USD. In the past month the price increased by 27.48%. In the past year, price increased by 43.92%.
IMNM Latest News, Press Relases and Analysis
IMNM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About IMNM
Company Profile
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Bothell, Washington and currently employs 118 full-time employees. The company went IPO on 2020-10-02. The firm is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The firm's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Company Info
IMMUNOME INC
18702 N. Creek Parkway, Suite 100
Bothell WASHINGTON 19341 US
CEO: Purnanand D. Sarma
Employees: 155
Phone: 16103213700
IMMUNOME INC / IMNM FAQ
What does IMMUNOME INC do?
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Bothell, Washington and currently employs 118 full-time employees. The company went IPO on 2020-10-02. The firm is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The firm's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Can you provide the latest stock price for IMMUNOME INC?
The current stock price of IMNM is 19.76 USD. The price decreased by -1.64% in the last trading session.
Does IMNM stock pay dividends?
IMNM does not pay a dividend.
What is the ChartMill rating of IMMUNOME INC stock?
IMNM has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for IMMUNOME INC?
IMMUNOME INC (IMNM) operates in the Health Care sector and the Biotechnology industry.
What is IMMUNOME INC worth?
IMMUNOME INC (IMNM) has a market capitalization of 1.81B USD. This makes IMNM a Small Cap stock.
IMNM Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IMNM. When comparing the yearly performance of all stocks, IMNM is one of the better performing stocks in the market, outperforming 94.92% of all stocks.
IMNM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMNM. IMNM has a great financial health rating, but its profitability evaluates not so good.
IMNM Financial Highlights
Over the last trailing twelve months IMNM reported a non-GAAP Earnings per Share(EPS) of -2.95. The EPS increased by 63.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.4% | ||
| ROE | -84.4% | ||
| Debt/Equity | 0 |
IMNM Forecast & Estimates
18 analysts have analysed IMNM and the average price target is 26.18 USD. This implies a price increase of 32.49% is expected in the next year compared to the current price of 19.76.
For the next year, analysts expect an EPS growth of 55.41% and a revenue growth -22.42% for IMNM